Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary electroCore Announces First Quarter 2019 Financial Results
Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities  Company to host conference call and webcast today, May 14 , at 4:30pm ET BASKING RIDGE, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Toggle Summary electroCore to Announce First Quarter 2019 Financial Results on Tuesday, May 14
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report first quarter ended March 31, 2019 financial results after the close of the
Toggle Summary electroCore Selected for Innovation and Technology Payment Program Through NHS England
gammaCore™ chosen by NHS England to be funded by the Innovation and Technology Payment Program (ITP) for the period of April 2019 to April 2020 to support adoption in the U.K. LONDON and BASKING RIDGE, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc.  (“electroCore”) (Nasdaq: ECOR), a
Toggle Summary Real-World Evidence and Insights into gammaCore™ (nVNS) Mechanism of Action to be Presented at the American Academy of Neurology’s 71st Annual Meeting
BASKING RIDGE, N.J. , May 03, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that two oral presentations featuring non-invasive vagus nerve stimulation (nVNS) will be presented at the 71 st Annual Meeting of the American
Toggle Summary electroCore Announces Fourth Quarter and Full Year 2018 Financial Results
Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018 Company to host conference call and webcast today, March 27 , at 4:30pm ET BASKING RIDGE, N.J. , March 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,
Toggle Summary electroCore to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Wednesday, March 27
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , March 18, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will report fourth quarter and year ended December 31, 2018 financial results after
Toggle Summary electroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™
Data presented at the 3rd International Brain Stimulation Conference support the use of nVNS for treatment of mild traumatic brain injury and rheumatoid arthritis BASKING RIDGE, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage bioelectronic
Toggle Summary electroCore Appoints Multiple Industry Veterans to Key Management Positions
Dr. Tony Fiorino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer BASKING RIDGE, N.J. , March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of Dr.
Toggle Summary electroCore Announces Positive Coverage Policies of gammaCore Issued by Highmark
BASKING RIDGE, N.J. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Highmark, one of the nation’s top health insurers and the third largest Blue Cross Blue Shield affiliated company, has determined that
Toggle Summary electroCore and HealthyWomen Announce Partnership on Patient Program to Increase Awareness of Non-Drug Migraine Therapies
BASKING RIDGE, N.J. and NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc . (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a patient education initiative in partnership with HealthyWomen , the nation’s leading independent, nonprofit health information